SELLAS Life Sciences Announced Review Of Ongoing Phase 3 REGAL Clinical Trial Of Galinpepimut-S In Acute Myeloid Leukemia By IDMC
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of the Phase 3 REGAL clinical trial of Galinpepimut-S in Acute Myeloid Leukemia without any modifications. No safety or futility concerns were raised, and an interim analysis is anticipated by Q4 2024.
June 17, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences' Phase 3 REGAL trial for Galinpepimut-S in Acute Myeloid Leukemia will continue without modifications, as recommended by the IDMC. No safety or futility concerns were raised, and an interim analysis is expected by Q4 2024.
The IDMC's recommendation to continue the trial without modifications and the absence of safety or futility concerns are positive indicators for the ongoing development of Galinpepimut-S. This news is likely to boost investor confidence in SELLAS Life Sciences, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100